What if COVID-19 affects the child: which weapons and how to use them.
Identifieur interne : 000035 ( Main/Exploration ); précédent : 000034; suivant : 000036What if COVID-19 affects the child: which weapons and how to use them.
Auteurs : L. Anedda [Italie] ; L. Bianchini ; L. Cuzzolin ; G. Finco ; V. Fanos ; M A MarcialisSource :
- European review for medical and pharmacological sciences [ 2284-0729 ] ; 2021.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Adolescent (MeSH), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Anticoagulants (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Chloroquine (usage thérapeutique), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Facteurs immunologiques (usage thérapeutique), Facteurs âges (MeSH), Glucocorticoïdes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Immunoglobulines par voie veineuse (usage thérapeutique), Indice de gravité de la maladie (MeSH), Interféron alpha (usage thérapeutique), Lopinavir (usage thérapeutique), Nourrisson (MeSH), Nouveau-né (MeSH), Oséltamivir (usage thérapeutique), Oxygénation extracorporelle sur oxygénateur à membrane (MeSH), Ribavirine (usage thérapeutique), Ritonavir (usage thérapeutique), Récepteurs de surface cellulaire (usage thérapeutique), Thrombose (prévention et contrôle), Ventilation artificielle (MeSH), État de porteur sain (MeSH).
- MESH :
- analogues et dérivés : AMP, Alanine.
- prévention et contrôle : Thrombose.
- usage thérapeutique : AMP, Alanine, Anticoagulants, Anticorps monoclonaux humanisés, Antiviraux, Chloroquine, Facteurs immunologiques, Glucocorticoïdes, Hydroxychloroquine, Immunoglobulines par voie veineuse, Interféron alpha, Lopinavir, Oséltamivir, Ribavirine, Ritonavir, Récepteurs de surface cellulaire.
- Adolescent, Association médicamenteuse, Enfant, Enfant d'âge préscolaire, Facteurs âges, Humains, Immunisation passive, Indice de gravité de la maladie, Nourrisson, Nouveau-né, Oxygénation extracorporelle sur oxygénateur à membrane, Ventilation artificielle, État de porteur sain.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Adolescent (MeSH), Age Factors (MeSH), Alanine (analogs & derivatives), Alanine (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (therapy), Carrier State (MeSH), Child (MeSH), Child, Preschool (MeSH), Chloroquine (therapeutic use), Continuous Renal Replacement Therapy (MeSH), Drug Combinations (MeSH), Extracorporeal Membrane Oxygenation (MeSH), Glucocorticoids (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Immunoglobulins, Intravenous (therapeutic use), Immunologic Factors (therapeutic use), Infant (MeSH), Infant, Newborn (MeSH), Interferon-alpha (therapeutic use), Lopinavir (therapeutic use), Oseltamivir (therapeutic use), Receptors, Cell Surface (therapeutic use), Respiration, Artificial (MeSH), Ribavirin (therapeutic use), Ritonavir (therapeutic use), SARS-CoV-2 (MeSH), Severity of Illness Index (MeSH), Thrombosis (prevention & control).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antibodies, Monoclonal, Humanized, Anticoagulants, Antiviral Agents, Chloroquine, Glucocorticoids, Hydroxychloroquine, Immunoglobulins, Intravenous, Immunologic Factors, Interferon-alpha, Lopinavir, Oseltamivir, Receptors, Cell Surface, Ribavirin, Ritonavir.
- drug therapy : COVID-19.
- prevention & control : Thrombosis.
- therapy : COVID-19.
- Adolescent, Age Factors, Carrier State, Child, Child, Preschool, Continuous Renal Replacement Therapy, Drug Combinations, Extracorporeal Membrane Oxygenation, Humans, Immunization, Passive, Infant, Infant, Newborn, Respiration, Artificial, SARS-CoV-2, Severity of Illness Index.
Abstract
Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.
DOI: 10.26355/eurrev_202104_25744
PubMed: 33928620
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">What if COVID-19 affects the child: which weapons and how to use them.</title>
<author><name sortKey="Anedda, L" sort="Anedda, L" uniqKey="Anedda L" first="L" last="Anedda">L. Anedda</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Pediatrics, University of Cagliari, Cagliari, Italy. gabriele.finco@unica.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>School of Pediatrics, University of Cagliari, Cagliari</wicri:regionArea>
<wicri:noRegion>Cagliari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bianchini, L" sort="Bianchini, L" uniqKey="Bianchini L" first="L" last="Bianchini">L. Bianchini</name>
</author>
<author><name sortKey="Cuzzolin, L" sort="Cuzzolin, L" uniqKey="Cuzzolin L" first="L" last="Cuzzolin">L. Cuzzolin</name>
</author>
<author><name sortKey="Finco, G" sort="Finco, G" uniqKey="Finco G" first="G" last="Finco">G. Finco</name>
</author>
<author><name sortKey="Fanos, V" sort="Fanos, V" uniqKey="Fanos V" first="V" last="Fanos">V. Fanos</name>
</author>
<author><name sortKey="Marcialis, M A" sort="Marcialis, M A" uniqKey="Marcialis M" first="M A" last="Marcialis">M A Marcialis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33928620</idno>
<idno type="pmid">33928620</idno>
<idno type="doi">10.26355/eurrev_202104_25744</idno>
<idno type="wicri:Area/Main/Corpus">000065</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000065</idno>
<idno type="wicri:Area/Main/Curation">000065</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000065</idno>
<idno type="wicri:Area/Main/Exploration">000065</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">What if COVID-19 affects the child: which weapons and how to use them.</title>
<author><name sortKey="Anedda, L" sort="Anedda, L" uniqKey="Anedda L" first="L" last="Anedda">L. Anedda</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Pediatrics, University of Cagliari, Cagliari, Italy. gabriele.finco@unica.it.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>School of Pediatrics, University of Cagliari, Cagliari</wicri:regionArea>
<wicri:noRegion>Cagliari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bianchini, L" sort="Bianchini, L" uniqKey="Bianchini L" first="L" last="Bianchini">L. Bianchini</name>
</author>
<author><name sortKey="Cuzzolin, L" sort="Cuzzolin, L" uniqKey="Cuzzolin L" first="L" last="Cuzzolin">L. Cuzzolin</name>
</author>
<author><name sortKey="Finco, G" sort="Finco, G" uniqKey="Finco G" first="G" last="Finco">G. Finco</name>
</author>
<author><name sortKey="Fanos, V" sort="Fanos, V" uniqKey="Fanos V" first="V" last="Fanos">V. Fanos</name>
</author>
<author><name sortKey="Marcialis, M A" sort="Marcialis, M A" uniqKey="Marcialis M" first="M A" last="Marcialis">M A Marcialis</name>
</author>
</analytic>
<series><title level="j">European review for medical and pharmacological sciences</title>
<idno type="eISSN">2284-0729</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Adolescent (MeSH)</term>
<term>Age Factors (MeSH)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antibodies, Monoclonal, Humanized (therapeutic use)</term>
<term>Anticoagulants (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (therapy)</term>
<term>Carrier State (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Continuous Renal Replacement Therapy (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Extracorporeal Membrane Oxygenation (MeSH)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Immunization, Passive (MeSH)</term>
<term>Immunoglobulins, Intravenous (therapeutic use)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Infant (MeSH)</term>
<term>Infant, Newborn (MeSH)</term>
<term>Interferon-alpha (therapeutic use)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Receptors, Cell Surface (therapeutic use)</term>
<term>Respiration, Artificial (MeSH)</term>
<term>Ribavirin (therapeutic use)</term>
<term>Ritonavir (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Thrombosis (prevention & control)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Adolescent (MeSH)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Anticoagulants (usage thérapeutique)</term>
<term>Anticorps monoclonaux humanisés (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Facteurs âges (MeSH)</term>
<term>Glucocorticoïdes (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Immunisation passive (MeSH)</term>
<term>Immunoglobulines par voie veineuse (usage thérapeutique)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Interféron alpha (usage thérapeutique)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Nourrisson (MeSH)</term>
<term>Nouveau-né (MeSH)</term>
<term>Oséltamivir (usage thérapeutique)</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane (MeSH)</term>
<term>Ribavirine (usage thérapeutique)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Récepteurs de surface cellulaire (usage thérapeutique)</term>
<term>Thrombose (prévention et contrôle)</term>
<term>Ventilation artificielle (MeSH)</term>
<term>État de porteur sain (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antibodies, Monoclonal, Humanized</term>
<term>Anticoagulants</term>
<term>Antiviral Agents</term>
<term>Chloroquine</term>
<term>Glucocorticoids</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulins, Intravenous</term>
<term>Immunologic Factors</term>
<term>Interferon-alpha</term>
<term>Lopinavir</term>
<term>Oseltamivir</term>
<term>Receptors, Cell Surface</term>
<term>Ribavirin</term>
<term>Ritonavir</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Thrombose</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Anticoagulants</term>
<term>Anticorps monoclonaux humanisés</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Facteurs immunologiques</term>
<term>Glucocorticoïdes</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulines par voie veineuse</term>
<term>Interféron alpha</term>
<term>Lopinavir</term>
<term>Oséltamivir</term>
<term>Ribavirine</term>
<term>Ritonavir</term>
<term>Récepteurs de surface cellulaire</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Age Factors</term>
<term>Carrier State</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Continuous Renal Replacement Therapy</term>
<term>Drug Combinations</term>
<term>Extracorporeal Membrane Oxygenation</term>
<term>Humans</term>
<term>Immunization, Passive</term>
<term>Infant</term>
<term>Infant, Newborn</term>
<term>Respiration, Artificial</term>
<term>SARS-CoV-2</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Association médicamenteuse</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Facteurs âges</term>
<term>Humains</term>
<term>Immunisation passive</term>
<term>Indice de gravité de la maladie</term>
<term>Nourrisson</term>
<term>Nouveau-né</term>
<term>Oxygénation extracorporelle sur oxygénateur à membrane</term>
<term>Ventilation artificielle</term>
<term>État de porteur sain</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33928620</PMID>
<DateCompleted><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>05</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2284-0729</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>25</Volume>
<Issue>8</Issue>
<PubDate><Year>2021</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>European review for medical and pharmacological sciences</Title>
<ISOAbbreviation>Eur Rev Med Pharmacol Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>What if COVID-19 affects the child: which weapons and how to use them.</ArticleTitle>
<Pagination><MedlinePgn>3325-3337</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">25744</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.26355/eurrev_202104_25744</ELocationID>
<Abstract><AbstractText>Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anedda</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>School of Pediatrics, University of Cagliari, Cagliari, Italy. gabriele.finco@unica.it.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bianchini</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cuzzolin</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Finco</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Fanos</LastName>
<ForeName>V</ForeName>
<Initials>V</Initials>
</Author>
<Author ValidYN="Y"><LastName>Marcialis</LastName>
<ForeName>M A</ForeName>
<Initials>MA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Italy</Country>
<MedlineTA>Eur Rev Med Pharmacol Sci</MedlineTA>
<NlmUniqueID>9717360</NlmUniqueID>
<ISSNLinking>1128-3602</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C118348">Robo3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>49717AWG6K</RegistryNumber>
<NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>I031V2H011</RegistryNumber>
<NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
<SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002353" MajorTopicYN="N">Carrier State</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000079664" MajorTopicYN="N">Continuous Renal Replacement Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>7</Hour>
<Minute>9</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2021</Year>
<Month>5</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33928620</ArticleId>
<ArticleId IdType="doi">10.26355/eurrev_202104_25744</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><noCountry><name sortKey="Bianchini, L" sort="Bianchini, L" uniqKey="Bianchini L" first="L" last="Bianchini">L. Bianchini</name>
<name sortKey="Cuzzolin, L" sort="Cuzzolin, L" uniqKey="Cuzzolin L" first="L" last="Cuzzolin">L. Cuzzolin</name>
<name sortKey="Fanos, V" sort="Fanos, V" uniqKey="Fanos V" first="V" last="Fanos">V. Fanos</name>
<name sortKey="Finco, G" sort="Finco, G" uniqKey="Finco G" first="G" last="Finco">G. Finco</name>
<name sortKey="Marcialis, M A" sort="Marcialis, M A" uniqKey="Marcialis M" first="M A" last="Marcialis">M A Marcialis</name>
</noCountry>
<country name="Italie"><noRegion><name sortKey="Anedda, L" sort="Anedda, L" uniqKey="Anedda L" first="L" last="Anedda">L. Anedda</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000035 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000035 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33928620 |texte= What if COVID-19 affects the child: which weapons and how to use them. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33928620" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |